178 related articles for article (PubMed ID: 17049192)
21. Development and characterization of ligand-appended liposomes for multiple drug therapy for pulmonary tuberculosis.
Bhardwaj A; Kumar L; Narang RK; Murthy RS
Artif Cells Nanomed Biotechnol; 2013 Feb; 41(1):52-9. PubMed ID: 22889361
[TBL] [Abstract][Full Text] [Related]
22. A Long-term Co-perfused Disseminated Tuberculosis-3D Liver Hollow Fiber Model for Both Drug Efficacy and Hepatotoxicity in Babies.
Srivastava S; Pasipanodya JG; Ramachandran G; Deshpande D; Shuford S; Crosswell HE; Cirrincione KN; Sherman CM; Swaminathan S; Gumbo T
EBioMedicine; 2016 Apr; 6():126-138. PubMed ID: 27211555
[TBL] [Abstract][Full Text] [Related]
23. Lung specific stealth liposomes as antitubercular drug carriers in guinea pigs.
Pandey R; Sharma S; Khuller GK
Indian J Exp Biol; 2004 Jun; 42(6):562-6. PubMed ID: 15260105
[TBL] [Abstract][Full Text] [Related]
24. Activity of diclofenac used alone and in combination with streptomycin against Mycobacterium tuberculosis in mice.
Dutta NK; Mazumdar K; Dastidar SG; Park JH
Int J Antimicrob Agents; 2007 Oct; 30(4):336-40. PubMed ID: 17644321
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of the BacT/ALERT PZA kit in comparison with the BACTEC 460TB PZA for testing Mycobacterium tuberculosis susceptibility to pyrazinamide.
Aragón LM; Garrigó M; Moreno C; Español M; Coll P
J Antimicrob Chemother; 2007 Sep; 60(3):655-7. PubMed ID: 17615155
[TBL] [Abstract][Full Text] [Related]
26. Significant increases in the levels of liver enzymes in mice treated with anti-tuberculosis drugs.
Lenaerts AJ; Johnson CM; Marrieta KS; Gruppo V; Orme IM
Int J Antimicrob Agents; 2005 Aug; 26(2):152-8. PubMed ID: 15953708
[TBL] [Abstract][Full Text] [Related]
27. [Effectiveness of liposome-incorporated streptomycin in experimental tuberculosis in mice].
Vladimirskiĭ MA; Ladygina GA; Tentsova AI
Antibiotiki; 1983 Jan; 28(1):23-6. PubMed ID: 6830199
[TBL] [Abstract][Full Text] [Related]
28. Effects of weak acids, UV and proton motive force inhibitors on pyrazinamide activity against Mycobacterium tuberculosis in vitro.
Wade MM; Zhang Y
J Antimicrob Chemother; 2006 Nov; 58(5):936-41. PubMed ID: 16950824
[TBL] [Abstract][Full Text] [Related]
29. Azole antifungals as novel chemotherapeutic agents against murine tuberculosis.
Ahmad Z; Sharma S; Khuller GK
FEMS Microbiol Lett; 2006 Aug; 261(2):181-6. PubMed ID: 16907718
[TBL] [Abstract][Full Text] [Related]
30. [A study on the mechanisms of mycobacterial clearance induced by CpG-oligodeoxynucleotides in mice].
Ren T; Liang YJ; Cai YY; Li CY; Mei J; Yuan ZH; Tao MF; Tian M; Zhao B
Zhonghua Jie He He Hu Xi Za Zhi; 2008 Jan; 31(1):46-50. PubMed ID: 18366907
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of M. tuberculosis in vitro in monocytes and in mice by aminomethylene pyrazinamide analogs.
Chung WJ; Kornilov A; Brodsky BH; Higgins M; Sanchez T; Heifets LB; Cynamon MH; Welch J
Tuberculosis (Edinb); 2008 Sep; 88(5):410-9. PubMed ID: 18674969
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics of pyrazinamide in children suffering from pulmonary tuberculosis.
Roy V; Tekur U; Chopra K
Int J Tuberc Lung Dis; 1999 Feb; 3(2):133-7. PubMed ID: 10091878
[TBL] [Abstract][Full Text] [Related]
33. In vitrouptake and antimycobacterial activity of liposomal usnic acid formulation.
Lira MC; Siqueira-Moura MP; Rolim-Santos HM; Galetti FC; Simioni AR; Santos NP; Tabosa Do Egito ES; Silva CL; Tedesco AC; Santos-Magalhães NS
J Liposome Res; 2009; 19(1):49-58. PubMed ID: 19515007
[TBL] [Abstract][Full Text] [Related]
34. Pyrazinamide serum levels in childhood tuberculosis.
Thee S; Detjen A; Wahn U; Magdorf K
Int J Tuberc Lung Dis; 2008 Sep; 12(9):1099-101. PubMed ID: 18713511
[TBL] [Abstract][Full Text] [Related]
35. Rapid determination of growth inhibition of Mycobacterium tuberculosis by GC-MS/MS quantitation of tuberculostearic acid.
Cai G; Pauli GF; Wang Y; Jaki BU; Franzblau SG
Tuberculosis (Edinb); 2013 May; 93(3):322-9. PubMed ID: 23454100
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice.
Deol P; Khuller GK; Joshi K
Antimicrob Agents Chemother; 1997 Jun; 41(6):1211-4. PubMed ID: 9174172
[TBL] [Abstract][Full Text] [Related]
37. Niosomes as a potential drug delivery system for increasing the efficacy and safety of nystatin.
El-Ridy MS; Abdelbary A; Essam T; El-Salam RM; Kassem AA
Drug Dev Ind Pharm; 2011 Dec; 37(12):1491-508. PubMed ID: 21707323
[TBL] [Abstract][Full Text] [Related]
38. Glycoside-bearing liposomal delivery systems against macrophage-associated disorders involving Mycobacterium leprae and Mycobacterium tuberculosis.
Medda S; Das N; Mahato SB; Mahadevan PR; Basu MK
Indian J Biochem Biophys; 1995 Jun; 32(3):147-51. PubMed ID: 7590855
[TBL] [Abstract][Full Text] [Related]
39. [Th 13-14 and PZA and CS in the treatment of chronic cavitary tuberculosis with bacterial resistance to classic antibacterial drugs].
Zunić D
Tuberkuloza; 1966; 18(5):429-40. PubMed ID: 16296047
[No Abstract] [Full Text] [Related]
40. Pyrazinamide plasma concentrations in young children with tuberculosis.
McIlleron H; Willemse M; Schaaf HS; Smith PJ; Donald PR
Pediatr Infect Dis J; 2011 Mar; 30(3):262-5. PubMed ID: 21416694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
